$TOI
Oncology Institute, Inc. Stock $toi

$toi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024013444 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$94.67M	$85.79M	$324.2M
YoY Change	24.25%	20.11%	28.42%
Cost Of Revenue	$82.70M	$71.41M	$264.7M
YoY Change	33.18%	27.98%	32.08%
Gross Profit	$11.97M	$14.38M	$59.57M
YoY Change	-15.11%	-8.0%	14.36%
Gross Profit Margin	12.64%	16.76%	18.37%
Selling, General & Admin	$28.45M	$28.09M	$113.9M
YoY Change	-1.31%	-5.01%	-4.88%
% of Gross Profit	237.71%	195.35%	191.11%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.489M	$1.573M	$5.873M
YoY Change	17.34%	31.96%	33.14%
% of Gross Profit	12.44%	10.94%	9.86%
Operating Expenses	$28.45M	$29.67M	$119.7M
YoY Change	-1.31%	-3.57%	0.03%
Operating Profit	-$17.97M	-$15.29M	-$60.15M
YoY Change	-45.32%	1.01%	-26.6%
Interest Expense	-$1.985M	-$1.941M	-$6.777M
YoY Change	37.56%	-20.78%	66.02%
% of Operating Profit
Other Income/Expense, Net	-$1.917M	-$1.839M	$691.0K
YoY Change	-165.81%	-111.38%	-99.16%
Pretax Income	-$19.89M	-$19.07M	-$83.10M
YoY Change	-33.6%	67.65%	91223.08%
Income Tax	$0.00	-$314.0K	-$36.00K
% Of Pretax Income
Net Earnings	-$19.89M	-$15.29M	-$67.88M
YoY Change	-33.7%	74.96%	-44755.92%
Net Earnings / Revenue	-21.01%	-17.82%	-20.93%
Basic Earnings Per Share	-$0.22		-$0.92
Diluted Earnings Per Share	-$0.22	-$0.21	-$0.92
COMMON SHARES
Basic Shares Outstanding	74.31M shares	73.75M shares	73.75M shares
Diluted Shares Outstanding	74.23M shares		73.75M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.83M	$82.86M	$82.86M
YoY Change	18.87%	12.26%	12.26%
Cash & Equivalents	$36.06M	$33.49M
Short-Term Investments	$29.78M	$49.37M	$49.37M
Other Short-Term Assets	$4.678M	$4.049M	$4.049M
YoY Change	-32.61%	-41.47%	-41.47%
Inventory	$11.55M	$13.68M	$13.68M
Prepaid Expenses
Receivables	$58.76M	$42.36M	$42.36M
Other Receivables	$368.0K	$551.0K	$551.0K
Total Short-Term Assets	$141.2M	$143.5M	$143.5M
YoY Change	18.69%	10.03%	10.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.00M	$40.05M	$40.05M
YoY Change	11.67%	368.61%	21.22%
Goodwill	$7.230M	$7.230M
YoY Change	58.87%	-66.24%
Intangibles	$17.13M	$17.90M
YoY Change	-0.56%	-0.3%
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$568.0K	$561.0K	$561.0K
YoY Change	7.78%	17.61%	17.61%
Total Long-Term Assets	$63.34M	$65.75M	$65.75M
YoY Change	-45.24%	-49.91%	-49.91%
TOTAL ASSETS
Total Short-Term Assets	$141.2M	$143.5M	$143.5M
Total Long-Term Assets	$63.34M	$65.75M	$65.75M
Total Assets	$204.5M	$209.2M	$209.2M
YoY Change	-12.83%	-20.04%	-20.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.02M	$14.43M	$14.43M
YoY Change	75.92%	53.96%	53.96%
Accrued Expenses	$18.36M	$16.76M	$16.76M
YoY Change	49.96%	14.82%	-0.6%
Deferred Revenue	$964.0K	$545.0K
YoY Change	10.17%	-52.15%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$45.77M	$34.79M	$34.79M
YoY Change	52.13%	17.05%	17.05%
LONG-TERM LIABILITIES
Long-Term Debt	$88.39M	$86.83M	$86.83M
YoY Change	7.6%	7.7%	7.7%
Other Long-Term Liabilities	$273.0K	$30.57M	$30.57M
YoY Change	-64.31%	3421.77%	9.02%
Total Long-Term Liabilities	$88.66M	$117.4M	$117.4M
YoY Change	6.93%	44.06%	8.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.77M	$34.79M	$34.79M
Total Long-Term Liabilities	$88.66M	$117.4M	$117.4M
Total Liabilities	$163.2M	$152.2M	$152.2M
YoY Change	19.83%	9.91%	9.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.0M	-$146.2M
YoY Change	78.38%	131.68%
Common Stock	$8.000K	$8.000K
YoY Change	14.29%	14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.30M	$57.03M	$57.03M
YoY Change
Total Liabilities & Shareholders Equity	$204.5M	$209.2M	$209.2M
YoY Change	-12.83%	-20.04%	-20.04%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$19.89M	-$15.29M	-$67.88M
YoY Change	-33.7%	74.96%	-44755.92%
Depreciation, Depletion And Amortization	$1.489M	$1.573M	$5.873M
YoY Change	17.34%	31.96%	33.14%
Cash From Operating Activities	-$15.88M	-$3.895M	-$36.32M
YoY Change	2.79%	-72.17%	-41.2%
INVESTING ACTIVITIES
Capital Expenditures	$610.0K	$857.0K	$4.567M
YoY Change	-66.83%	-57.04%	-17.4%
Acquisitions			$4.456M
YoY Change			-48.05%
Other Investing Activities	$20.00M	$12.49M	$67.21M
YoY Change	-1.2%	-140.84%	-153.3%
Cash From Investing Activities	$19.39M	$11.63M	$62.64M
YoY Change	5.36%	-135.71%	-147.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$893.0K
YoY Change			-109.92%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$938.0K	-1.777M	-6.847M
YoY Change	-45.11%	109.8%	-107.43%
NET CHANGE
Cash From Operating Activities	-$15.88M	-3.895M	-36.32M
Cash From Investing Activities	$19.39M	11.63M	62.64M
Cash From Financing Activities	-$938.0K	-1.777M	-6.847M
Net Change In Cash	$2.567M	5.958M	19.48M
YoY Change	107.02%	-112.57%	-119.25%
FREE CASH FLOW
Cash From Operating Activities	-$15.88M	-$3.895M	-$36.32M
Capital Expenditures	$610.0K	$857.0K	$4.567M
Free Cash Flow	-$16.49M	-$4.752M	-$40.88M
YoY Change	-4.62%	-70.29%	-39.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cerritos
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90703
CY2023	dei	City Area Code CityAreaCode	562
CY2023	dei	Local Phone Number LocalPhoneNumber	735-3226
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14010000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	617000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9261000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	130418000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	58354000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8547000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24494000	usd
CY2022Q4	us-gaap	Assets Assets	261665000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9372000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5498000	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73265621	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	165045	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146150000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57025000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209240000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5873000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	401257000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-77018000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6777000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	286000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-704000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6086000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83104000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67877000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73748660	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-67877000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73748660	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3663000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16980000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73748660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72793497	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73748660	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001799191
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherReceivablesNetCurrent
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherReceivablesNetCurrent
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity File Number EntityFileNumber	001-39248
CY2023	dei	Entity Registrant Name EntityRegistrantName	The Oncology Institute, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3562323
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	18000 Studebaker Rd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	41600000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74312921	shares
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	Costa Mesa, California
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33488000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	49367000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	59796000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42360000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39816000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	551000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13678000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4049000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6918000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	143493000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10883000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29169000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17904000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17957000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7230000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	21418000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	561000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	477000	usd
CY2023Q4	us-gaap	Assets Assets	209240000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14429000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6363000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	255000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13996000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14595000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34788000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29720000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26486000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22060000	usd
CY2023Q4	toi	Derivative Warrant Liabilities Noncurrent DerivativeWarrantLiabilitiesNoncurrent	636000	usd
CY2022Q4	toi	Derivative Warrant Liabilities Noncurrent DerivativeWarrantLiabilitiesNoncurrent	350000	usd
CY2023Q4	toi	Derivative Earnout Liabilities Noncurrent DerivativeEarnoutLiabilitiesNoncurrent	0	usd
CY2022Q4	toi	Derivative Earnout Liabilities Noncurrent DerivativeEarnoutLiabilitiesNoncurrent	803000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3082000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3960000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	86826000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80621000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	365000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	868000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	32000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	108000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	152215000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	138490000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1019000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75879025	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74145251	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73265621	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	165045	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	165045	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	165045	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	204186000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	186250000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1733774	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1019000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63082000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	123175000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	261665000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	324239000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	252483000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4411000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	334434000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-81951000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4082000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1843000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-803000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-59215000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	878000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	24200000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	183000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	501000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81860000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-91000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-243000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-83068000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	68000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72793497	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16980000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80605600	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	104159000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	858000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	9000000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	413000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27419000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	123175000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-83068000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	126000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17810000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4456000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	8577000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9595000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	117508000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57025000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-83068000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	152000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5873000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4411000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	6205000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2444000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	16867000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9944000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	17810000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27683000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	286000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1843000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-803000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-59215000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	878000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	24200000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	249000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-378000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2631000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1020000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-76000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-263000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	183000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2020000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	476000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	30000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-21000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4564000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20285000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4385000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1732000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-66000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-620000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3128000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4282000	usd
CY2023	toi	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-5806000	usd
CY2022	toi	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-5404000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	84000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	157000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3357000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2349000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-255000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	123000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5057000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6187000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5324000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3801000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-443000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1157000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36315000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61756000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4567000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5529000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	81258000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	62640000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131614000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	110000000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	toi	Payments For Financing Of Insurance Payments PaymentsForFinancingOfInsurancePayments	3269000	usd
CY2022	toi	Payments For Financing Of Insurance Payments PaymentsForFinancingOfInsurancePayments	5009000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2584000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	509000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	101000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	58000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1019000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9000000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	126000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	858000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	413000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6847000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92206000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	19478000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-101164000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14010000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115174000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33488000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14010000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	403000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	150000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4506000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	224000	usd
CY2023	toi	Deferred Consideration As Part Of Practice Acquisitions DeferredConsiderationAsPartOfPracticeAcquisitions	1813000	usd
CY2022	toi	Deferred Consideration As Part Of Practice Acquisitions DeferredConsiderationAsPartOfPracticeAcquisitions	0	usd
CY2023	toi	Discount On Convertible Debt DiscountOnConvertibleDebt	0	usd
CY2022	toi	Discount On Convertible Debt DiscountOnConvertibleDebt	28160000	usd
CY2023	toi	Non Cash Financed Insurance Premiums NonCashFinancedInsurancePremiums	1253000	usd
CY2022	toi	Non Cash Financed Insurance Premiums NonCashFinancedInsurancePremiums	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	182000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023	toi	Number Of Oncologists And Mid Level Professionals Within Three States Minimum NumberOfOncologistsAndMidLevelProfessionalsWithinThreeStatesMinimum	119	oncologist
CY2023	toi	Number Of Clinic Locations NumberOfClinicLocations	69	cliniclocation
CY2023Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	5	state
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates under different assumptions or conditions. Significant items subject to such estimates and assumptions include judgements related to revenue recognition, estimated accounts receivable and the allowance for credit losses, useful lives and recoverability of long-lived and intangible assets, recoverability of goodwill, fair values of acquired identifiable assets and assumed liabilities in business combinations, fair value of intangible assets and goodwill, fair value of share-based compensation, fair value of liability classified instruments, and judgements related to deferred income taxes.</span></div>
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	16867000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9944000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	toi	Defined Contribution Plan Required Service Period DefinedContributionPlanRequiredServicePeriod	P2M
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1271000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1108000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42360000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39816000	usd
CY2022Q1	toi	Accounts Receivable After Allowance For Credit Loss Remaining Amount AccountsReceivableAfterAllowanceForCreditLossRemainingAmount	20007000	usd
CY2023	toi	Accounts Receivable Allowance For Credit Loss Recovery Reversal AccountsReceivableAllowanceForCreditLossRecoveryReversal	11000	usd
CY2022	toi	Accounts Receivable Allowance For Credit Loss Recovery Reversal AccountsReceivableAllowanceForCreditLossRecoveryReversal	169000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	2031000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	307000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	324239000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	252483000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	545000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1139000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	220000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	594000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	220000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13678000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9261000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	72279000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	134000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	72150000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	121101000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	384000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	120723000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	72150000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	usd
CY2023Q4	toi	Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year5 DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	72150000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	72892000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	47831000	usd
CY2022Q4	toi	Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year5 DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	120723000	usd
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	249000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	3	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	242000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	274000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	16867000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9944000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6180000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3506000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10883000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8547000	usd
CY2023	us-gaap	Depreciation Depreciation	2864000	usd
CY2022	us-gaap	Depreciation Depreciation	1526000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5518000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5310000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	545000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1139000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1002000	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3010000	usd
CY2023Q4	toi	Business Combination Consideration Transferred Other Current BusinessCombinationConsiderationTransferredOtherCurrent	2206000	usd
CY2022Q4	toi	Business Combination Consideration Transferred Other Current BusinessCombinationConsiderationTransferredOtherCurrent	802000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1124000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1100000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3601000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3234000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13996000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14595000	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1250000	usd
CY2023Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.0875
CY2023Q4	toi	Number Of Instalments Payable NumberOfInstalmentsPayable	10	installment
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	122000	usd
CY2023Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	1002000	usd
CY2023	toi	Operating And Short Term Lease Cost OperatingAndShortTermLeaseCost	7596000	usd
CY2022	toi	Operating And Short Term Lease Cost OperatingAndShortTermLeaseCost	6364000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7556000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6002000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	59000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	62000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	11000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8000	usd
CY2023	us-gaap	Lease Cost LeaseCost	8905000	usd
CY2022	us-gaap	Lease Cost LeaseCost	7401000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3957000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6243000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11096000	usd
CY2022	toi	Right Of Use Assets Obtained During Current Year In Exchange For Operating Lease Liability RightOfUseAssetsObtainedDuringCurrentYearInExchangeForOperatingLeaseLiability	11668000	usd
CY2023	toi	Lessee Operating Lease Number Of Clinic Lease Term Extensions LesseeOperatingLeaseNumberOfClinicLeaseTermExtensions	7	cliniclocation
CY2023	toi	Operating Lease Modification Liability Increase Decrease OperatingLeaseModificationLiabilityIncreaseDecrease	3297000	usd
CY2023	toi	Operating Lease Modification Liability Increase Decrease Net Of Lease Incentives OperatingLeaseModificationLiabilityIncreaseDecreaseNetOfLeaseIncentives	3303000	usd
CY2023	toi	Operating Lease Modification Increase Decrease In Rent Expenses OperatingLeaseModificationIncreaseDecreaseInRentExpenses	67000	usd
CY2022	toi	Lessee Operating Lease Number Of Clinic Lease Term Extensions LesseeOperatingLeaseNumberOfClinicLeaseTermExtensions	2	cliniclocation
CY2022	toi	Lessee Operating Lease Number Of Office Lease Term Extensions LesseeOperatingLeaseNumberOfOfficeLeaseTermExtensions	2	corporateoffice
CY2022	toi	Operating Lease Modification Liability Increase Decrease OperatingLeaseModificationLiabilityIncreaseDecrease	2186000	usd
CY2022	toi	Operating Lease Modification Liability Increase Decrease Net Of Lease Incentives OperatingLeaseModificationLiabilityIncreaseDecreaseNetOfLeaseIncentives	2052000	usd
CY2022	toi	Operating Lease Modification Increase Decrease In Rent Expenses OperatingLeaseModificationIncreaseDecreaseInRentExpenses	39000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	110000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	110000000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	83000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	85000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-43000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-78000	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-121000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	40000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-76000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-135000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-135000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-128000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-108000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-263000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-243000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17432000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-62000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-101000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	20000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	14000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Transaction Costs Amount EffectiveIncomeTaxRateReconciliationTransactionCostsAmount	30000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Transaction Costs Amount EffectiveIncomeTaxRateReconciliationTransactionCostsAmount	684000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1970000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1411000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	-60000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	387000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Earnout Expense Amount EffectiveIncomeTaxRateReconciliationEarnoutExpenseAmount	169000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Earnout Expense Amount EffectiveIncomeTaxRateReconciliationEarnoutExpenseAmount	12435000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation162m Analysis Amount EffectiveIncomeTaxRateReconciliation162mAnalysisAmount	4000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation162m Analysis Amount EffectiveIncomeTaxRateReconciliation162mAnalysisAmount	0	usd
CY2023	toi	Effective Income Tax Rate Reconciliation162m Deferred Haircut EffectiveIncomeTaxRateReconciliation162mDeferredHaircut	131000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation162m Deferred Haircut EffectiveIncomeTaxRateReconciliation162mDeferredHaircut	1433000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation163 L Interest Expense Limitation EffectiveIncomeTaxRateReconciliation163LInterestExpenseLimitation	2242000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation163 L Interest Expense Limitation EffectiveIncomeTaxRateReconciliation163LInterestExpenseLimitation	885000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Dfp Derivative Expense EffectiveIncomeTaxRateReconciliationDFPDerivativeExpense	184000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Dfp Derivative Expense EffectiveIncomeTaxRateReconciliationDFPDerivativeExpense	5082000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	569000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Prior Year Deferred True Ups EffectiveIncomeTaxRateReconciliationPriorYearDeferredTrueUps	224000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Prior Year Deferred True Ups EffectiveIncomeTaxRateReconciliationPriorYearDeferredTrueUps	2100000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Other State Items Amount EffectiveIncomeTaxRateReconciliationOtherStateItemsAmount	0	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Other State Items Amount EffectiveIncomeTaxRateReconciliationOtherStateItemsAmount	24000	usd
CY2023	toi	Effective Income Tax Rate Reconciliation Amended Return Amount EffectiveIncomeTaxRateReconciliationAmendedReturnAmount	40000	usd
CY2022	toi	Effective Income Tax Rate Reconciliation Amended Return Amount EffectiveIncomeTaxRateReconciliationAmendedReturnAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13538000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14856000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-243000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1204000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1293000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40359000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26357000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	1313000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	160000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	334000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4969000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3497000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	21000	usd
CY2023Q4	toi	Deferred Tax Asset Charitable Contributions DeferredTaxAssetCharitableContributions	1000	usd
CY2022Q4	toi	Deferred Tax Asset Charitable Contributions DeferredTaxAssetCharitableContributions	1000	usd
CY2023Q4	toi	Deferred Tax Asset Tenant Improvement Allowance DeferredTaxAssetTenantImprovementAllowance	21000	usd
CY2022Q4	toi	Deferred Tax Asset Tenant Improvement Allowance DeferredTaxAssetTenantImprovementAllowance	43000	usd
CY2023Q4	toi	Deferred Tax Asset Rou Lease Liability DeferredTaxAssetROULeaseLiability	9446000	usd
CY2022Q4	toi	Deferred Tax Asset Rou Lease Liability DeferredTaxAssetROULeaseLiability	7913000	usd
CY2023Q4	toi	Deferred Tax Asset Financing Lease Liability DeferredTaxAssetFinancingLeaseLiability	261000	usd
CY2022Q4	toi	Deferred Tax Asset Financing Lease Liability DeferredTaxAssetFinancingLeaseLiability	177000	usd
CY2023Q4	toi	Deferred Tax Asset Unrealized Gain Loss DeferredTaxAssetUnrealizedGainLoss	42000	usd
CY2022Q4	toi	Deferred Tax Asset Unrealized Gain Loss DeferredTaxAssetUnrealizedGainLoss	112000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7736000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2530000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64157000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43505000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53979000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34915000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10178000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8590000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1595000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1507000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	8363000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	7013000	usd
CY2023Q4	toi	Deferred Tax Asset Financial Lease Asset DeferredTaxAssetFinancialLeaseAsset	261000	usd
CY2022Q4	toi	Deferred Tax Asset Financial Lease Asset DeferredTaxAssetFinancialLeaseAsset	176000	usd
CY2023Q4	toi	Deferred Tax Asset Irc174 Expenditures DeferredTaxAssetIRC174Expenditures	-9000	usd
CY2022Q4	toi	Deferred Tax Asset Irc174 Expenditures DeferredTaxAssetIRC174Expenditures	2000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10210000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8698000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	32000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	108000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53979000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34915000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19064000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20196000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53979000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	99000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	99000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	99000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	99000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75879025	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74145251	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73265621	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73265621	shares
CY2023	toi	Common Stock Votes Per Share CommonStockVotesPerShare	1	vote
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	163510	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	165045	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	165045	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	165045	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	165045	shares
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	100	shares
CY2023Q4	toi	Preferred Stock Maximum Percent Of Common Stock Allowed PreferredStockMaximumPercentOfCommonStockAllowed	0.049
CY2021Q4	toi	Class Of Warrant Or Right Threshold Number Of Business Days Before Sending Notice Of Redemption To Warrant Holders ClassOfWarrantOrRightThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders	3	d
CY2022Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	20000000	shares
CY2023	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1500000	shares
CY2023Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	5000000	shares
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	894000	usd
CY2023Q3	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	2000000	shares
CY2023Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	125000	usd
CY2022	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	5	businesscombination
CY2022	toi	Number Of Asset Acquired NumberOfAssetAcquired	1	assetacquisition
CY2023	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	businesscombination
CY2023	toi	Number Of Asset Acquired NumberOfAssetAcquired	0	assetacquisition
CY2023	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	114000	usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	790000	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	326349000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	256756000	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-83177000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	38000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32032000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14128000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17904000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29075000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11118000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17957000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3078000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3075000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3050000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2923000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2818000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2960000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17904000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3009000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2885000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7230000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	21418000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	21418000	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	26626000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2679000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	4736000	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	16867000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	9944000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7230000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	21418000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-83068000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	152000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	64000	usd
CY2023	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-83068000	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	88000	usd
CY2023	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	-15191000	usd
CY2022	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	20000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67877000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	68000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73748660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72793497	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-83068000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	152000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	64000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	20656000	usd
CY2023	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-83068000	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-20568000	usd
CY2023	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	-15191000	usd
CY2022	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	-3588000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-67877000	usd
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	5100809	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80605600	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-77018000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-81951000	usd
CY2023Q4	us-gaap	Assets Assets	209240000	usd
CY2022Q4	us-gaap	Assets Assets	261665000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	563000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	9150000	usd

Files In Submission

Name	View Source	Status
0001628280-24-013444-index-headers.html	Edgar Link	pending
0001628280-24-013444-index.html	Edgar Link	pending
0001628280-24-013444.txt	Edgar Link	pending
0001628280-24-013444-xbrl.zip	Edgar Link	pending
ex311-certificationrule13a.htm	Edgar Link	pending
ex312-certificationrule13a.htm	Edgar Link	pending
ex321-ceocertificationsect.htm	Edgar Link	pending
ex322-cfocertificationsect.htm	Edgar Link	pending
ex971toisection16erroneous.htm	Edgar Link	pending
exhibit231-consentofbdousa.htm	Edgar Link	pending
exhibit45-descriptionofcap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
toi-20231231.htm	Edgar Link	pending
toi-20231231.xsd	Edgar Link	pending
toi-20231231_g1.gif	Edgar Link	pending
toi-20231231_g2.gif	Edgar Link	pending
toi-20231231_g3.jpg	Edgar Link	pending
toi-20231231_g4.jpg	Edgar Link	pending
toi-20231231_g5.jpg	Edgar Link	pending
toi-20231231_def.xml	Edgar Link	unprocessable
toi-20231231_lab.xml	Edgar Link	unprocessable
toi-20231231_pre.xml	Edgar Link	unprocessable
toi-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
toi-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOI
Oncology Institute, Inc. Stock $toi

2024 Q1 Form 10-K Financial Statement

#000162828024013444 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOI Oncology Institute, Inc. Stock $toi

2024 Q1 Form 10-K Financial Statement

#000162828024013444 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOI
Oncology Institute, Inc. Stock $toi